Donate

Industry News

CSL Behring Announces Availability of Next Generation HeliTrax® System for People with Hemophilia A

December 1, 2010

 Custom software platform is first internet-enabled mobile application to interface directly with patient management systems used by hemophilia treatment centers   KING OF PRUSSIA, Pa., Dec. 1, 2010 /PRNewswire/ — CSL Behring announced today the availability of the next generation HeliTrax® System as part of a specially designed software platform for Apple’s iPhone®, iPod touch®, […]

BioRx Offers Free 2010 Kids Hemophilia Calendar

November 24, 2010

Link to article November 9, 2009 (Cincinnati, Ohio) – BioRx, a specialty pharmaceutical company, announces the availability of a free 2010 calendar to the hemophilia community. The annual BioRx Kids Hemophilia Calendar features artwork from children who either have a bleeding disorder or have a sibling or parent with a bleeding disorder. To produce the […]

BioRx Offers Scholarships to Bleeding Disorders Community

November 24, 2010

Link to article September 1, 2010 (Cincinnati, Ohio) BioRx and Hemophilia of North Carolina announce the availability of four 2011 BioRx Educational Scholarships in the amount of $2,000 each to individuals with bleeding disorders. The scholarships will be awarded for the 2011-2012 school year, and the deadline for submitting applications is May 1, 2011. BioRx […]

Novo Nordisk announced the U.S. Food and Drug Administration (FDA) has approved NovoSeven® RT (Coagulation Factor VIIa [Recombinant] Room Temperature Stable) in an 8 mg vial size.

September 2, 2010

Novo Nordisk announced on August 10 that the U.S. Food and Drug Administration (FDA) has approved NovoSeven® RT (Coagulation Factor VIIa [Recombinant] Room Temperature Stable) in an 8 mg vial size, making the hemophilia A or B with inhibitors treatment available in 1, 2, 5 and 8 mg vials. The 8 mg vial allows a rapid initiation […]

Novo Nordisk provides a development update on two new investigational drugs for the bleeding disorders community.

August 30, 2010

The company’s ultra fastacting recombinant factor VIIa is progressing to a phase 3 trial after the successful completion of a phase 2 safety, pharmacokinetics and efficacy trial; the phase 3 trial is currently being designed.  A phase 3 trial for the factor XIII drug was recently been completed and showed that, compared to a historic […]

Pfizer Receives FDA Approval for Prefilled Dual-Chamber Syringe for Use in the Treatment of Hemophilia A

August 9, 2010

Pfizer Press Release Pfizer is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted approval for the use of a Prefilled Dual-Chamber Syringe for administration of XYNTHA® Antihemophilic Factor (Recombinant) Plasma/Albumin-Free to hemophilia A patients. XYNTHA is an injectable recombinant factor VIII product previously approved by the FDA for both the […]

BioRx President Phil Rielly Wins Ernst & Young Entrepreneur of the Year® Award

July 28, 2010

(Cincinnati, Ohio)  July 20, 2010 – Philip Rielly, President and Co-founder of specialty pharmacy BioRx LLC,  has received the Ernst & Young Entrepreneur Of The Year® 2010 Award in the Healthcare category in South  Central Ohio and Kentucky.  According to Ernst & Young LLP, the award recognizes outstanding entrepreneurs  who are building and leading dynamic, […]

Winners announced for 2010 BioRx Educational Scholarships

July 21, 2010

News Release                        June 21, 2010 (Cincinnati, Ohio)   BioRx, a specialty pharmacy, and Hemophilia of North Carolina, a non-profit organization that assists and educates persons affected by bleeding disorders, announce the winners of the 2010 BioRx Educational Scholarships.  Each of the winners receives a $2,000 scholarship.  The scholarships are funded by BioRx through an educational grant, […]

Real-World Experience Confirms Low Inhibitor Rate Established in ADVATE Controlled Clinical Studies for Hemophilia Patients

July 14, 2010

Buenos Aires, Argentina, (July 13, 2010) – Baxter International Inc. (NYSE: BAX) today announced final E.U./U.S. post-authorization safety surveillance (PASS) data that support the safety and efficacy profile of ADVATE [Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method] previously documented in prospective clinical trials in a new study published in the journal Hemophilia. see more…advate_pass

BioRX Announces New National Director of Operations

June 24, 2010

Randy Broyles, RPh has joined BioRx as National Director of Operations. See more…Randy Boyles

CSL Behring Launches 2 New Programs this month for Patients & Caregivers

April 27, 2010

1. FactorPlus: This is a new free product trial program for Helixate FS. Some of the highlights of the program: Shipment of trial product directly to patients homes (physician can choose where product should go to i.e. HTC or patients home) Inclusion of ancillary supplies with every shipment A welcome kit with helpful resources Improved availability […]

TODAY GRIFOLS INTRODUCES MIX2VIAL FILTER TRANSFER SETS

April 27, 2010

Los Angeles, California (April 23, 2010). Grifols USA, LLC (Grifols) today announced the availability of the Mix2Vial™ transer set for the reconstitution and administratioon of Grifols’ coagulation therapies. TheMix2Vial™   is a plastic, needle-free transfer device with a built-in 15 micron filter specifically designed to be used with the Sterile Water for Injection diluent packaged with Grifols […]

A Tribute to Dr. Robert Janco

March 10, 2010

Disease Area Lead, Pfizer Hematology Trusted colleague, outstanding clinician and friend of the hemophilia community, Dr. Robert “Bob” Janco passed away on March 9 after a short but aggressive illness. Bob had a wealth of experience in the diagnosis and clinical management of adults and children with congenital bleeding disorders. He most recently served at Disease […]

Infusion Set Needles [Manufactured by Nipro for Exelint]: Recall

January 26, 2010

Exel/Exelint Huber needles, Exel/Exelint Huber Infusion Sets Exel/Exelint “Securetouch+” Safety Huber Infusion Sets Audience: Hospital Risk Managers, Surgical Service personnel FDA notified healthcare professionals of a Class I recall of Exel/Exelint Huber needles, Exel/Exelint Huber Infusion Sets and Exel/Exelint “Securetouch+” Safety Huber Infusion Sets, manufactured by Nipro Medical Corporation for Exelint International Corporation due to […]

340B Prime Vendor Program, managed by Apexus, and the Hemophilia Alliance announced today an innovative collaborative effort to assist participating federally funded hemophilia treatment centers.

January 14, 2010

IRVING, Texas/ Lansdale, Pa (January 14, 2010) – The 340B Prime Vendor Program, managed by Apexus, and  the Hemophilia Alliance announced today an innovative collaborative effort to assist participating federally funded hemophilia treatment centers in maximizing the benefits of 340B Drug Pricing Program and Prime Vendor Program discounts.  The two organizations are working together to […]

Octapharma Receives Orphan Drug Exclusivity Approval for wilate(R …

January 13, 2010

Octapharma Receives Orphan Drug Exclusivity Approval for wilate(R … FOXBusiness “Orphan drug exclusivity confirms Octapharma’s decision to focus exclusively on the treatment of von Willebrand patients. Wilate has a combination of two … Octapharma Receives Orphan Drug Exclusivity Approval for wilate(R …      

Bayer is now accepting internship applications for the 2010 Bayer Hemophilia Leadership Development Program

December 22, 2009

The Bayer Hemophilia Leadership Development Program was developed with input from several members of the hemophilia community who saw a need for a program to develop future leaders in the bleeding disorders community. With their support, Bayer HealthCare Pharmaceuticals created an eight-week, paid summer internship at Bayer HealthCare’s U.S. Headquarters in Wayne, New Jersey. During […]

Octapharma USA Announces FDA Approval of wilate(R) – the First Replacement Therapy Developed Specifically for von Willebrand Dis

December 8, 2009

Octapharma USA Announces FDA Approval of wilate(R) – the First Replacement Therapy Developed Specifically for von Willebrand Disease  Milestone Marks Swiss Company’s Entrance into the U.S. Blood Coagulation Market HOBOKEN, N.J., Dec. 7 /PRNewswire/ — Octapharma USA today announced the U.S. Food and Drug Administration has approved wilate® for the treatment of spontaneous and trauma-induced […]

The WFH receives the largest humanitarian aid donation in its history

December 1, 2009

NEWS RELEASE:   Donation represents more than 40 million international units to the WFH  (Montreal, December 2, 2009): As part of its continued commitment to hemophilia care around the world, Wyeth, now a part of Pfizer, has pledged more than  40 million international units (IUs) of factor concentrates to the World Federation of Hemophilia (WFH). This […]

1st Person with Hemophilia Reaches Mt. Rainier Summit to Raise Money for Inner-city Youth and International Bleeding Disorder Assistance Jeff Salantai

November 10, 2009

News Release Cincinnati, Ohio (November 9, 2009) —   On August 5, 2009, two BioRx employees, Jeff Salantai and Eric Hill, began hiking to the summit of Mt. Rainier.  They successfully reached the 14,410-foot summit on August 6.   Hill says, “We hoped to reach one of the largest peaks in the U.S., and we achieved […]

Wyeth Announces Recipients of the Soozie Courter “Sharing a Brighter Tomorrow” Hemophilia Scholarship Program

October 1, 2009

  Program Marks Continued Commitment to Education and Assistance to Hemophilia Community (Click Here for Announcement)  Collegeville, Pa., September 29, 2009 division of Wyeth (NYSE:WYE), today announced the recipients of the Soozie Courter “Sharing a Brighter Tomorrow” Hemophilia Scholarship Program for the 2009 assistance for higher education to individuals with hemophilia. Since 2002, Wyeth has donated […]

BioRx and Bayer Healthcare Offer Free

September 28, 2009

Cincinnati, Ohio (September 28, 2009) (Click Here for PDF)— Bayer HealthCare and BioRx, a specialty pharmaceutical company, announce the availability of Quest for Infusion: Nate Goes to Camp, a new children’s book about hemophilia.  Quest for Infusion: Nate Goes to Camp, written by Chris Perretti Barnes and illustrated by Michael Graham, is the story of […]

PPTA LAUNCHES NEW WEBSITE TOOL

September 28, 2009

FOR IMMEDIATE RELEASE  September 23, 2009  Contact: Kara Flynn                                                 Kym H. Kilbourne (443) 458-4669                                                           (443) 458-4682 (443) 370-1177 (cellular)                                           (443) 995-2102 (cellular) kflynn@pptaglobal.org                                            kkilbourne@pptaglobal.org PPTA LAUNCHES NEW WEBSITE TOOL (Click Here for PDF) Enhancement to help potential plasma donors find plasma centers  ANNAPOLIS, MD (September 23, 2009) – Visitors to DonatingPlasma.org can more […]

Ablynx Initiates Phase II Clinical Trial for Alx-0081

September 3, 2009

  01 Sep 2009 Ablynx announced the initiation of a Phase II study for its anti-thrombotic Nanobody ALX-0081, a first-in-class Nanobody targeting von Willebrand Factor (vWF)GHENT, BELGIUM | September 1, 2009 | Ablynx [Euronext Brussels: ABLX] today announced the initiation of a Phase II study for its anti-thrombotic Nanobody ALX-0081, a first-in-class Nanobody targeting von […]

Ablynx Announces Positive Phase I Results for Subcutaneous Administration of it’s Ant-thrombotic NanobodyR (ALX-0681)

August 19, 2009

GHENT, Belgium, 18 August 2009 – Ablynx [Euronext Brussels: ABLX] today announced the positive results from its double-blind, randomized, placebo-controlled, single and multiple dose Phase I study with ALX-0681, a subcutaneous formulation of its novel anti-thrombotic Nanobody® that selectively targets von Willebrand factor (vWF). The positive Phase I data support the progression of ALX-0681 towards […]

Bayer HealthCare Launches Hemophilia Self-Infusion Training Program

July 28, 2009

News Release   Innovative BayCuff™ Program Empowers Young Members of Hemophilia A Community to Take Control of Their Treatment WAYNE, NJ, July 9, 2009 – Today, Bayer HealthCare Pharmaceuticals launched the BayCuff™ self-infusion training program, an educational initiative designed to make infusion of recombinant factor VIII easier for both patients with hemophilia A and for their […]

Google News Alert for: von Willibrand

July 20, 2009

Google News Alert for: von Willibrand Bio/Data Corporation Launches vW Select(TM) – The World’s First … SYS-CON Media – Montvale,NJ,USA vW Select is the first and only complete assay that measures the functional activity of the von Willebrand Factor. A deficiency of von Willebrand Factor …

Wyeth Pharmaceuticals, Catalyst collaborating on hemophilia drug

July 20, 2009

Tuesday, June 30, 2009, 11:36am EDT Wyeth Pharmaceuticals, Catalyst collaborating on hemophilia drug Philadelphia Business Journal Wyeth Pharmaceuticals said Tuesday that it has formed an exclusive worldwide collaboration with Catalyst Biosciences Inc. to develop treatments for hemophilia and other bleeding conditions. Collegeville, Pa.-based Wyeth Pharmaceuticals, a division of Wyeth (NYSE:WYE) said it will pay South […]


Sign up for E-mails, Dateline Magazine, and other ways to stay connected.